Company Analysis
Sign in

Humacyte, Inc. (HUMA)

Nasdaq: HUMA · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.9
◀ Past 4.2● Present 3.2▶ Future 4.3
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Humacyte, Inc.

Nine metrics read from its own filings, by tense
Headline grade
3.9/10
◀ Past4.225% of the headline
● Present3.235% of the headline
▶ Future4.340% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.2/1025% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed
0.6/10

Has it survived what it has been through?

4 warning events since 2020; the latest 2026-07-31.

weight 22% of this tense · 6th percentile among 159 sector filers · read for itself

From the record

Humacyte, Inc.'s filings since 2020 show 4 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-07-31); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-05-13); an auditor change (8-K item 4.01, the latest 2021-08-30) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate
4.9/10

What has it actually done, year after year?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 103 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one.
What the record cannot read
Fewer than three filed years of revenue on file.
How it was reasoned
family median, 103 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Humacyte, Inc.'s track record is put at 4.9 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate
5.6/10

How has it treated the people who own it?

SI estimate 5.6/10, confidence 35 of 100 (one part).

weight 33% of this tense · 56th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 44% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Humacyte, Inc.'s shareholder treatment is put at 5.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 44% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.2/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
1.4/10

Is it financially healthy right now?

ROE -1313%: lost 1313¢ per shareholder dollar. Leverage 97%: owes 97¢ per asset dollar.

weight 45% of this tense · 14th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Humacyte, Inc. lost about 1313 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 7 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 97 cents per dollar of assets, and net share issuance: its share count grew 33.5% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 19% of its family
  • return on equitybottom 2% of its family
  • gross profit against assetsbottom 3% of its family
  • the share count against the year beforebottom 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
2.5/10

How strong is its position in its industry?

bottom 25% of 102 in its family; net margin -2003.6%.

weight 22% of this tense · 25th percentile among 102 sector filers · read for its customers

From the record

Humacyte, Inc.'s standing among 102 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 23% by size; a net margin of -2003.6% ranks in the bottom 27% (its annual reports).

What it rests on

  • revenue against the family$2.0Mbottom 23% of its family
  • net margin-2003.6%bottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
6.3/10

What are the people in charge doing?

top 38% of 110 in its family for leadership; chief executive since 2021.

weight 33% of this tense · 62nd percentile among 110 sector filers · read for its shareholders

From the record

Humacyte, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Niklason, Laura E (President, CEO and Director, as filed), filing under that title since 2021-08-27, 5.2 years (top 48% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.2 years (bottom 44%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 9%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge2 in three years among 15 peopletop 9% of its family
  • the median years the people in charge have filed5.2 yearsbottom 44% of its family
  • the chief executive's years on the record5.2 yearstop 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.3/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed
3.0/10

How much room does it have to grow?

bottom 30% of 92 in its family for room to expand.

weight 33% of this tense · 30th percentile among 92 sector filers · read for itself

From the record

Humacyte, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $51 million against debt of $35 million leaves 13.2% of its assets as net cash, bottom 19% of its family; cash from operations less capital spending is -5197.5% of revenue (bottom 15%); a gross margin of -376.1% (bottom 1%); research spending of 3400.5% of revenue (top 15%) (its annual report).

What it rests on

  • cash less debt against assets13.2%bottom 19% of its family
  • cash from operations less capital spending against revenue-5197.5%bottom 15% of its family
  • gross margin-376.1%bottom 1% of its family
  • research spending against revenue3400.5%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate
4.9/10

What could actually drive growth from here?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 101 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one.
What the record cannot read
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned
family median, 101 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Humacyte, Inc.'s growth drivers is put at 4.9 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate
5.1/10

Did its newest year beat what its own record pointed to?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 73 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 73 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Humacyte, Inc.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton HUMA · research, not advice